In the present study, we used the adenovirus vector, which exhibits very high gene transduction efficiency. 15) Because a variety of tumor cells contain few Coxsackie adenovirus receptors (CAR), 16) we used a recombinant adenovirus vector with a fiber mutation containing the Arg-Gly-Asp (RGD) sequence in the fiber knob. This fiber-mutant vector possesses higher transduction and anti-tumor activities compared to conventional adenovirus vectors when used in cytokine-gene therapy against melanoma. 17, 18) In the present study, ovarian carcinoma OV-HM cells were transfected with a chemokineencoding recombinant vector, AdRGD-mCCL19 or AdRGD-mXCL1, and both the in vitro chemotactive activity and the in vivo tumor-suppressive response were investigated.
MATERIALS AND METHODS
Cell Lines and Animals OV-HM ovarian carcinoma cell line 19) were kindly provided by Dr. Hiromi Fujiwara (School of Medicine, Osaka University, Japan) and were maintained in RPMI 1640 supplemented with 10% heat-inactivated FBS. A549 human lung carcinoma cells and human embryonic kidney (HEK) 293 cells were cultured in DMEM supplemented with 10% FBS. Murine pre-B lymphoma L1.2 cells and their stable transfectants, L1.2/mCCR7 and L1.2/mXCR cells, which expressing specific receptor for CCL19 and XCL1, respectively, were maintained in RPMI 1640 supplemented with 10% heat-inactivated FBS and 2-ME (50 mM, Life Technologies). All the cell lines were cultured at 37°C in a humidified atmosphere with 5% CO 2 . Female B6C3F1 mice were purchased from SLC Inc. (Hamamatsu, Japan) and used at 6-8 weeks of age. All of the experimental pro-cedures were in accordance with the Osaka University guidelines for the welfare of animals in experimental neoplasia.
Construction of Adenovirus Vectors
The replicationdeficient adenovirus vectors containing a fiber mutation, which were used in this study, were developed based on the adenovirus type 5 backbone with deletions of the E1 and E3 regions. 20) The RGD sequence was inserted into the HI loop of the fiber knob using a two-step method developed by Mizuguchi et al. 21) Murine chemokine genes derived from pT7T3D-Pac-mCCL19 and pExCell-mCXL1 were used as sources of cDNA. Recombinant adenovirus vectors with the RGD fiber mutation, AdRGD-mCCL19 and AdRGD-mXCL1, carrying the chemokine cDNA under the control of the cytomegalovirus (CMV) promoter, were constructed by an improved in vitro ligation method described previously. 20, 22) The luciferase expressing adenovirus vectors with the RGD fiber mutation (AdRGD-luc), serving as a negative control, is identical to the AdRGD-mCCL19 and AdRGD-mXCL1 vectors and contains the luciferase gene in the expression cassette ( Fig. 1 ). Conventional adenovirus vector expressing lusiferase (Ad-Luc) was also developed by Mizuguchi et al. 22) The adenovirus vectors were propagated in 293 cells and purified by cesium chloride gradient ultracentrifugation. Virus particle (VP) was accomplished spectrophotometrically. 23) The titer (tissue culture infectious dose 50 ; TCID 50 ) was determined by plaque-forming assay using 293 cells. 24, 25) Gene Expression by AdRGD-Luc or Conventional Ad-Luc in OV-HM Ovarian Carcinoma Cells 2ϫ10 3 of OV-HM cells in a 96-well plate were treated with Ad-Luc or AdRGD-Luc at 1250, 2500, 5000, and 10000 viral particles/ cell for 1.5 h, respectively. Cells were washed with PBS and cultured for an additional 48 h. Subsequently, the cells were washed, collected, and their luciferase activity was measured using the Luciferase Assay System (Promega, U.S.A.) and Microlumat Plus LB96 (Perkin Elmer, U.S.A.) after the cells were lysed with the Luciferase Cell Culture Lysis (Promega, U.S.A.) according to the manufacturer's instruction.
In Vitro Chemotaxis Assay The AdRGD-Luc and indicated AdRGD-chemokine were tranfected into A549 cells for 2 h at a multiplicity of infection (MOI) of 50, and the cells were washed twice with PBS and cultured in media containing 10% FBS. The cells were subsequently washed after 24 h cultivation, and incubated with an assay medium (phenol red-free RPMI 1640 containing 0.5% bovine serum albumin and 20 mM HEPES, pH 7.4) for another 24 h. The resulting conditioned medium was collected, and its chemoattractant activity was measured by an in vitro chemotaxis assay across a polycarbonate membrane with 5-mm pores (Chemotaxicell-24; Kurabo, Osaka, Japan) using L1.2 transfectants expressing the specific receptor for chemokines. The culture supernatants of intact A549 cells, AdRGD-Luc-transfected A549 cells, and chemokine gene-transduced A549 cells were prepared. These samples and recombinant chemokines dissolved in the assay medium were added to a 24-well culture plate. Cells expressing specific receptors for CCL19 (L1.2/CCR7) or XCL1 (L1.2/XCR1) were suspended in the assay medium (1ϫ10 6 cells) and placed in a Chemotaxicell-24 installed on each well. Likewise, parental L1.2 cells for these transfectants were prepared and added to the Chemotaxicell-24. Cell migration was allowed for 2 h at 37°C in a 5% CO 2 atmos-phere. The cells that migrated to the lower well were lysed and quantitated using a PicoGreen dsDNA quantitation reagent (Invitrogen, Tokyo, Japan). The data are expressed as meanϮS.E. of the triplicate results and the migration activity was expressed in terms of the percentage of the input cells. Recombinant chemokines (mouse: mCCL19 and mXCL1) corresponding to each specific receptor (CCR7 and XCR1) were purchased from DakoCytomation (Kyoto, Japan) and used as a positive control.
Evaluation of Growth of OV-HM Cells Transfected with Chemokine-Encoding Adenovirus Vectors in Immunocompetent Mice OV-HM cells were transfected with
AdRGD-mCCL19, AdRGD-mXCL1, or AdRGD-Luc as a control, at a MOI of 10 for 24 h. The cells were then harvested and washed with PBS three times and 1ϫ10 6 cells were inoculated intradermally into the flank of B6C3F1 mice. An aliquot of the OV-HM cells infected with AdRGD-mCCL19, AdRGD-mXCL1 or AdRGD-Luc at a MOI of 10 were cultured for an additional 48 h, and cell viability was examined by MTT assay. For in vivo evaluation of OV-HM cell growth, tumor volume was calculated by measuring the length and width of the tumor, twice a week. The mice were euthanized when one of the two measurements was greater than 15 mm.
RESULTS

OV-HM Tumor Cells Transfected with Fiber-Mutant Adenovirus Vector Induced Higher Gene Expression Than That Induced by Conventional Vector
To evaluate the gene transfection efficiency of the fiber-mutant adenovirus vector developed for this study, OV-HM cells were transfected with conventional adenovirus vector or fiber-mutant adenovirus vector at indicated particles/cell and luciferase activity was measured. The results shown in Fig. 2 demonstrated that luciferase gene expression induced by fiber-mutant vector was much higher than that induced by conventional adenovirus vector. For example, at 10000 VP/cell transfection, 16-fold greater gene expression was obtained in response to fiber-mutant vector than to Ad-Luc. This demonstrated that the insertion of the RGD peptide into the viral fiber enhanced transfection efficiency to OV-HM cells via the adenovirus vector.
Expression of Murine CCL19 and XCL1 by Transfection with Chemokine-Encoding Adenovirus Vector To verify that the CCL19 and XCL1 produced by AdRGD-mCCL19 and AdRGD-mXCL1, respectively, were biologically functional, A549 cells were infected with the vectors for 2 h, and the culture supernatants were harvested after an additional 48 h. In the present study, human lung carcinoma A549 cells were used instead of murine tumor cells because of the very strong background chemotactic activity in the culture supernatant of the latter. 16) Using an in vitro chemotaxis assay, we investigated whether A549 cells transfected with each chemokine gene-carrying AdRGD could secrete chemokine protein in its biologically active form into culture supernatants. As shown in Table 1 , the culture supernatants of A549 cells transfected with AdRGD-mCCL19 (mCCL19/ A549) or AdRGD-mXCL1 (mXCL1/A549) could induce greater migration of cells expressing the corresponding chemokine receptors than those from intact A549 cells or A549 cells transfected with AdRGD-Luc (Luc/A549). The migration of L1.2 cells was not observed in wells containing recombinant chemokines, and only low-level migration was observed in culture supernatants from intact A549, Luc/ A549, mXCL1/A549, and mCCL19/A549. These results demonstrated that all AdRGDs could deliver their encoded chemokine gene to target cells, and that transfected cells could secrete the chemokine protein, which maintained its original chemoattractant activity.
Anti-tumor Effect in Vivo by Transfection of Chemokine CCL19 into OV-HM Cells via Fiber-Mutant
Adenovirus Vector OV-HM ovarian carcinoma cells transfected with 10 MOI of AdRGD-mCCL19, AdRGD-mXCL1 or AdRGD-Luc as the control vector, were intradermally inoculated into B6C3F1 immunocompetent mice to evaluate their effects on tumor growth in vivo. In the present study, 10 MOI of Ad vectors were chosen for transfection because that higher MOI induced the cytotoxicity of OV-HM cells (data not shown). As shown in Figs. 3A and B , the transfection of AdRGD-mCCL19 resulted in significant suppression of tumor growth, while that of AdRGD-mXCL1 did not show any difference from that with AdRGD-Luc. To exclude the possibility that the suppression of tumor cell growth by AdRGD-mCCL19 was due to the cytotoxicity of the adenovirus or chemokine, OV-HM cells transfected with AdRGD-mCCL19, AdRGD-mXCL1 or AdRGD-Luc were cultured for 48 h, and cell viability was measured by the MTT assay. The in vitro growth of the cells infected with these vectors was essentially identical to that of control cells (Fig. 3C) .
DISCUSSION
Cytokines or chemokines encoded by a viral vector are currently regarded as intriguing options for cancer gene immunotherapy. Adenovirus vector, which shows high gene transduction efficiency and which can infect both dividing and non-dividing cells, is widely used as a carrier for gene therapy. It has been reported that the initial process of adenovirus infection involves at least two sequential steps. The first step is the attachment of the virus to the cell surface, which occurs by binding of the fiber knob to the Coxsackie virus and Adenovirus Receptor (CAR). 26, 27) Following this, in the second step, the interaction between the RGD motif of the penton base with av integrins, the secondary host-cell receptors, facilitates internalization through receptor-mediated endocytosis. 28, 29) In other words, if the host cell surface lacks CAR, efficient gene transfer using a conventional adenovirus vector is difficult. Unfortunately, some malignant cells, including ovarian carcinoma, exhibit a resistance to adenovirus-mediated gene transduction due to low CAR expression on their surface. To overcome the low gene expression levels in CAR negative cells by adenovirus vectors, we constructed a fiber-mutant Ad vector with an integrin-targeting RGD peptide by a simple in vitro method. 20) The results of gene transfection in vitro (Fig. 2) demonstrated that OV-HM transfected using AdRGD-Luc carrying the luciferase gene significantly induced gene expression compared to that induced by the conventional Ad-Luc, suggesting that the recombinant adenovirus vector is a better option for cancer gene therapy.
We also inserted the murine chemokine cDNA of the CC family chemokine, CCL19, and C family chemokine, XCL1, into the E1 cassette of this fiber-mutant adenovirus vector, and AdRGD-mCCL19 and AdRGD-mXCL1 were developed. The expression of chemokine mRNA was reported pre- Chemotaxis assay was performed using L1.2 cells expressing specific receptors for CCL19 (L1.2/CCR7) or XCL1 (L1.2/XCR1). viously. 30) A chemotaxis assay of chemokine-encoding vectors was conducted in vitro to evaluate the biological activity of these vectors. The results demonstrated that the produced protein in the culture supernatants of cells infected with these vectors could efficiently cause migration of the specific receptor-expressing cells ( Table 1 ).
The C family chemokine, XCL1, has been widely used for cancer immunotherapy, but in general, XCL1 by itself did not induce notable anti-tumor effects, even though it is a chemoattractant for both T cells and NK cells. 31) The CC chemokine, CCL19, reportedly induces T cell and dendritic cell migration and exhibits tumor-suppressive effects in several mouse malignant cell models. 32, 33) Hillinger et al. reported that intratumoral injection of recombinant CCL19 led to significant systemic reduction in tumor volumes. CCL19treated mice exhibited remarkably increased infiltration of CD4 ϩ and CD8 ϩ T cell subsets as well as dendritic cells at the tumor sites. These cell infiltrates were accompanied by increases in several cytokines and chemokines such as IFNg, CXCL9, CXCL10, GM-CSF, and IL-12. 34) We have also shown that CCL19 and XCL1 elicited anti-tumor response, to some extent, through transfection into B16BL6 melanoma cells. But our study, which used eight chemokines to evaluate the anti-tumor effects in three tumor cell types, suggests that the tumor-suppressive activity of chemokine gene immunotherapy is very complicated and is greatly influenced by the type of tumor and activation state of the host's immune system. 30) Moreover, as we previously reported, 10) transfection with the chemokine CCL27 induced tumor-suppressive effects, whereas another chemokine, CX 3 CL1, did not show any notable anti-tumor activity. However, both of these chemokines induced the accumulation of T cells as well as NK cells at the tumor site. Our results indicated that the distribution of immune cells that have migrated to the tumor and the angiogenic or angiostatic activity may play an important role in the anti-tumor response.
Several groups have reported much stronger anti-tumor activity when using chemokines as adjuvants with other agents. [35] [36] [37] [38] [39] In the present study, CCL19 could not induce complete tumor regression, but merely inhibited its growth. On other hand, remarkable anti-tumor activity could be obtained when XCL1 was combined with cytokines or tranfected into dendritic cells. 40, 41) A recent report showed that combination of both XCL1 and CXCL10 can enhance the efficiency of adoptive T cell therapy for EG7 tumor cells via accumulation of effector T cells in tumor tissue. 42) Many factors are likely to influence the tumor-suppressive effects of chemokines, but the relatively weak anti-tumor activity and long-term immuno-protective effects of chemokines may be mainly related to the activation level of migrating immune cells. In other words, not only the accumulation but also the activation of immune cells migrating into tumors is important in cancer immunotherapy using chemokines. Therefore, combination therapy using both chemokines and cytokines will increase the anti-tumor effects and improve cancer immunotherapy.
Fig. 3. Growth of OV-HM Tumor Cells in B6C3F1 Mice Transfected with Chemokine-Encoding Adenovirus Vectors
Mice were inoculated intradermally in the flank with 1ϫ10 6 OV-HM cells (100 ml in RPMI 1640) at a MOI of 10 and with AdRGD-mCCL19 or AdRGD-mXCL1 for 24 h. Tumor volume was calculated after measuring the length and width of the tumor at indicated periods of time. Data are expressed as the meanϮS.E. Intact OV-HM cells were used as control (untreated), and the OV-HM cells infected with AdRGD-Luc were inoculated into B6C3F1 mice for vector-control. Animals were euthanized when one of the two measured values were greater than 15 mm. At least six mice were used in each group. (A) Individual tumor size in each group and (B) average size in each group. (C) MTT assay results that evaluated the growth of chemokine-gene-transduced OV-HM cells in vitro. OV-HM cells were infected with AdRGD-mCCL19, AdRGD-mXCL1 or AdRGD-Luc at a MOI of 10 for 24 h, and then cultured for 48 h. Cell viability was examined by MTT assay. Data are expressed as the meansϮS.E. of triplicate results. Each of the analyses were performed at least three times.
